In vivo最新文献

{"title":"Evaluation Strategies for Tissue-engineered Tracheas: From <i>In Vitro</i> Characterization to <i>In Vivo</i> Assessment.","authors":"Ok Joo Lee, Hyun-Joo Lee, Ji Seung Lee, Moon Sik Oh, Harry Jung, Hyeonsun Kim, Chan Hum Park, Ilhwan Lee, Jinseo Yang, Jae Jun Lee, Hae Sang Park","doi":"10.21873/invivo.14052","DOIUrl":"https://doi.org/10.21873/invivo.14052","url":null,"abstract":"<p><p>The trachea plays a critical role in maintaining airway patency, ventilation, and mucociliary clearance, supported by its unique anatomical and structural features. Tracheal defects resulting from congenital anomalies, malignancies, trauma, or prolonged intubation present significant clinical challenges. Traditional reconstruction methods, such as end-to-end anastomosis and patch grafts, are often limited by technical feasibility and suboptimal outcomes. Recently, tissue-engineered tracheal scaffolds (TETs), particularly those fabricated using 3D bioprinting technologies, have emerged as promising alternatives due to their ability to mimic natural structures and integrate functional components. However, despite technological progress, no long-term successful clinical applications have been established to date, highlighting the need for robust and standardized preclinical evaluation frameworks. This review systematically analyzes current <i>in vitro</i> and <i>in vivo</i> methodologies used to assess the safety, biocompatibility, mechanical integrity, and functional performance of 3D printing-based TETs. By introducing a variety of analysis methods to evaluate the mechanical, physicochemical, and biocompatibility properties of TETs, this study aims to propose essential components for the evaluation of 3D-printed TETs.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 5","pages":"2490-2504"},"PeriodicalIF":1.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Salvage Chemotherapy on Survival Outcomes Following Immune Checkpoint Inhibitor Therapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.","authors":"Daisuke Abe, Takayuki Kimura, Satoru Koike, Hisatomo Tamaki, Sayumi Konya, Maya Kawamoto, Masahiro Umemoto, Mitsuo Sato, Mutsukazu Kitano, Takahiro Wakasaki, Ryuji Yasumatsu","doi":"10.21873/invivo.14100","DOIUrl":"https://doi.org/10.21873/invivo.14100","url":null,"abstract":"<p><strong>Background/aim: </strong>Immune checkpoint inhibitors (ICIs) have demonstrated clinical efficacy in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, it remains a matter of debate which patient populations derive clinical benefit from salvage chemotherapy (SCT) following disease progression after ICI therapy.</p><p><strong>Patients and methods: </strong>This retrospective study included 97 patients with R/M HNSCC who received ICI therapy (nivolumab or pembrolizumab). Patients were classified into SCT (n=54) and non-SCT (n=43) groups after ICI failure. Survival outcomes, response rates, and clinical variables were compared between groups.</p><p><strong>Results: </strong>The SCT group showed a significantly longer median overall survival (OS) compared to the non-SCT group (16.6 <i>vs.</i> 2.4 months, <i>p</i><0.0001). These findings indicate that patients who received SCT had markedly better outcomes. Multivariate analysis identified SCT [hazard ratio (HR)=4.93, <i>p</i><0.00001] and ECOG PS0,1 (HR=2.42, <i>p</i>=0.0257) as independent prognostic factors for OS. Patients treated with paclitaxel plus cetuximab (PTX + Cmab) had higher objective response rate (ORR) (50%) and disease control rate (DCR) (68.4%) compared to other regimens.</p><p><strong>Conclusion: </strong>SCT after ICI failure significantly improves survival in R/M HNSCC, particularly when using PTX+Cmab. Patients who received SCT had substantially better outcomes than those who did not. ECOG PS and sarcopenia status should be considered in treatment selection.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 5","pages":"2993-3000"},"PeriodicalIF":1.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-spin Redox Sensor for Electron Paramagnetic Resonance Studies of Tissue Redox State <i>In Vivo</i>: Validation of Data With a Conventional Spin Probe.","authors":"Dessislava Lazarova, Biliana Nikolova, Zhivko Zhelev, Plamen Getsov, Milka Mileva, Rumiana Bakalova, Ichio Aoki","doi":"10.21873/invivo.14069","DOIUrl":"https://doi.org/10.21873/invivo.14069","url":null,"abstract":"<p><strong>Background/aim: </strong>Redox imaging is one of the fastest growing areas in diagnostics of pathologies accompanied by redox imbalance. We describe a multi-spin redox sensor (RS) and its application for redox imaging in mice using electron paramagnetic resonance (EPR) spectroscopy.</p><p><strong>Materials and methods: </strong>The probe is composed of a quantum dot functionalized with a cyclodextrin shell, conjugated with nitroxide residues (TEMPO) and triphenylphosphonium to achieve intracellular delivery. The data were validated with a conventional spin probe, mito-TEMPO. Nitroxide probe (RS or mito-TEMPO) was injected intravenously in mice under anesthesia. Blood samples were collected from the tail vein at four time intervals within 2 hours and subjected immediately to analysis using EPR spectroscopy. Two hours after injection, mice were sacrificed, five organs were isolated, and tissue homogenates were prepared and subjected to EPR analysis.</p><p><strong>Results: </strong>RS had the same EPR contrast and significantly higher MRI contrast compared to mito-TEMPO. RS circulated longer in the bloodstream than mito-TEMPO, with both substances undergoing reduction in the blood. The distribution of RS and mito-TEMPO in different organs was equal, except for the brain. No adverse side effects were found in mice at the selected dose.</p><p><strong>Conclusion: </strong>Using a non-toxic nanoparticle in the chemical structure of RS as a carrier of nitroxide residues would enhance its translational relevance.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 5","pages":"2703-2710"},"PeriodicalIF":1.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Hidradenitis Suppurativa in Patients With Carpal Tunnel Syndrome: A Population-based Cohort Study.","authors":"Chih-Lung Wu, Yu-Jung Su, Hui-Chin Chang, Ya-Hsuan Wu, Yi-Sheng Jhang, Meng-Che Wu, Shiu-Jau Chen, Shuo-Yan Gau","doi":"10.21873/invivo.14093","DOIUrl":"https://doi.org/10.21873/invivo.14093","url":null,"abstract":"<p><strong>Background/aim: </strong>Carpal tunnel syndrome (CTS) and hidradenitis suppurativa (HS) are chronic inflammatory conditions that significantly affect quality of life. While both disorders have distinct manifestations, they share common risk factors such as obesity and systemic inflammation. This study aimed to evaluate whether CTS is associated with an increased risk of HS.</p><p><strong>Patients and methods: </strong>We conducted a retrospective cohort study using data from the TriNetX Global Health Research Network. Adults diagnosed with CTS were matched 1:1 with controls without CTS, based on age, sex, race, body mass index (BMI), comorbidities, socioeconomic status, and healthcare utilization. Individuals with prior HS or cancer were excluded. The primary outcome was new-onset HS, identified by ICD-10 codes. Hazard ratios (HRs) with 95% confidence intervals (CIs). Sensitivity analyses incorporated varied wash-out periods, alternative CTS definitions, and different follow-up durations.</p><p><strong>Results: </strong>After matching, 493,181 patients were included in each group. Over a 15-year follow-up period, patients with CTS showed a significantly higher risk of HS (HR=1.739; 95%CI=1.617-1.871). Sensitivity analyses validated the robustness of the results, with HRs ranging from 1.647 (95%CI=1.572-1.726) to 2.142 (95%CI=1.979-2.318) across different models. In stratified analyses, the association remained significant across all subgroups. Among males, the HR was 1.249 (95%CI=1.042-1.498), whereas among females, it was 1.739 (95%CI=1.606-1.884). Patients aged 18-64 years had an HR of 1.772 (95%CI=1.642-1.913), while those aged ≥65 years had an HR of 1.479 (95%CI=1.146-1.907).</p><p><strong>Conclusion: </strong>CTS is significantly associated with an increased risk of HS. These findings suggest a possible shared inflammatory pathway, and dermatologic comorbidities in CTS patients should be carefully considered.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 5","pages":"2931-2939"},"PeriodicalIF":1.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Myopic Control Effect of Defocus Incorporated Multiple Segments' Spectacle Lens With Atropine in High Myopia Population.","authors":"Chia-Yi Lee, Shun-Fa Yang, Jing-Yang Huang, Ie-Bin Lian, Chao-Kai Chang","doi":"10.21873/invivo.14095","DOIUrl":"https://doi.org/10.21873/invivo.14095","url":null,"abstract":"<p><strong>Background/aim: </strong>This study investigated the efficiency of combined atropine (ATR) and defocus incorporated multiple segments' (DIMS) spectacle lens <i>versus</i> ATR monotherapy in controlling high myopia in children.</p><p><strong>Patients and methods: </strong>A retrospective cohort study was performed, enrolling patients treated with either ATR monotherapy (n=35 eyes) or a combination of ATR and DIMS lenses (n=32 eyes). The primary outcomes were the spherical equivalent refraction (SER) progression and axial length (AXL) elongation, and were measured over a one year follow up period. Statistical comparisons were made using independent t-tests and generalized linear models.</p><p><strong>Results: </strong>After one year, the ATR group showed significantly greater SER progression (-0.38±0.14D) compared to the DIMS-ATR group (-0.15±0.09D) (<i>p</i><0.001). After the same period of time, AXL elongation was also significantly higher in the ATR group (0.13±0.07 mm) compared to the DIMS-ATR group (0.06±0.04 mm) (<i>p</i><0.001). Subgroup analysis indicated that a young initial age, high baseline SER, and longer initial AXL were associated with greater SER progression and AXL elongation in the ATR group (all <i>p</i><0.05). In addition, in the DIMS-ATR group, higher initial SER and AXL were independently associated with SER progression and AXL elongation, respectively (both <i>p</i><0.05).</p><p><strong>Conclusion: </strong>The combined ATR plus DIMS spectacle lenses was more effective in slowing myopia progression than ATR monotherapy in children with high myopia. This combined approach may be a preferable strategy for managing high-risk pediatric myopia.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 5","pages":"2950-2957"},"PeriodicalIF":1.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Enfortumab Vedotin Treatment in Patients Ineligible for the EV-301 Trial.","authors":"Kazutaka Nakamura, Yuki Kobari, Yudai Ishiyama, Hanae Kondo, Toru Inakawa, Yuki Nemoto, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Hiroaki Shimmura, Hiroshi Kobayashi, Yasunobu Hashimoto, Hideki Ishida, Tsunenori Kondo, Toshio Takagi","doi":"10.21873/invivo.14075","DOIUrl":"https://doi.org/10.21873/invivo.14075","url":null,"abstract":"<p><strong>Background/aim: </strong>The EV-301 trial demonstrated the efficacy of enfortumab vedotin (EV) as a third-line treatment for metastatic urothelial carcinoma (mUC), showing significant improvement in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy in patients previously treated with platinum-based therapy and immune checkpoint inhibitors. In real-world clinical practice, patients undergoing third-line treatment often have poor baseline health status, leading to the off-label use of EV in populations ineligible for clinical trials. This study aimed to evaluate the treatment outcomes of EV in both EV-301 trial-eligible and -ineligible patients.</p><p><strong>Patients and methods: </strong>Fifty-eight patients with mUC treated with EV across five Institutions were retrospectively evaluated and stratified based on the EV-301 trial eligibility criteria. Patients with an Eastern Cooperative Oncology Group performance status of ≥2, baseline hemoglobin level of <9 g/dl, creatinine clearance <30 ml/min, or other protocol-defined criteria were analyzed. Treatment outcomes were assessed for both groups.</p><p><strong>Results: </strong>Of the 58 patients, 33 (56.9%) met the EV-301 trial eligibility criteria. No significant differences were observed in PFS (median: 9.2 <i>vs.</i> 7.1 months, for eligible <i>vs.</i> ineligible patients) and OS (15.4 <i>vs.</i> 8.9 months). Although the objective response rate was higher in the eligible group (54.6% <i>vs.</i> 28.0%), there was no significant difference in the disease control rate (78.8% <i>vs.</i> 80.0%). Adverse events (AEs) of any grade were more frequent in the eligible group (93.9% <i>vs.</i> 64.0%), but the incidence of grade ≥3 AEs did not differ significantly (12.1% <i>vs.</i> 8.0%).</p><p><strong>Conclusion: </strong>The findings of this multi-institutional study highlight the feasibility of EV treatment in EV-301 trial-ineligible patients with mUC, supporting its potential applicability in both trial-eligible and -ineligible groups.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 5","pages":"2766-2776"},"PeriodicalIF":1.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Dose and Local Control in Five-fraction Stereotactic Body Radiotherapy for Hepatocellular Carcinoma.","authors":"Yuta Nishikawa, Ichiro Ogino, Yuki Mukai, Akihiro Funaoka, Yuriko Takeda, Masaharu Hata","doi":"10.21873/invivo.14090","DOIUrl":"https://doi.org/10.21873/invivo.14090","url":null,"abstract":"<p><strong>Background/aim: </strong>To retrospectively analyze the relationship between local control (LC) and the minimum dose covering 95% of the planning target volume (PTV D95%) in patients with hepatocellular carcinoma (HCC) treated with stereotactic body radiotherapy (SBRT).</p><p><strong>Patients and methods: </strong>Between May 2020 and March 2024, 72 HCC tumors in 59 patients were evaluated at Yokohama City University Medical Center. The prescribed dose ranged from 30-50 Gy in five fractions in accordance with the RTOG 1112 trial. However, PTV D95% was used for evaluation because of dose reductions near organs at risk.</p><p><strong>Results: </strong>The median follow-up period was 20 months. During this period, 13 patients died, and nine local recurrences were observed. The median PTV D95% was 38.9 Gy (range=10.6-48.5 Gy). The 1- and 2-year LC rates were 93.7% and 82.3%, respectively. Both univariate and multivariate analyses identified PTV D95% as a significant prognostic factor for LC [univariate: hazard ratio (HR)=0.882, 95% confidence interval (CI)=0.797-0.977, <i>p</i>=0.016; multivariate: HR=0.891, 95%CI=0.891-0.989, <i>p</i>=0.031]. Notably, no local recurrences were observed in patients with PTV D95% ≥40 Gy. Receiver operating characteristic analysis determined that 38 Gy was the optimal PTV D95% cut-off to prevent local recurrence, based on Youden's index.</p><p><strong>Conclusion: </strong>PTV D95% was a significant prognostic factor for LC in patients with HCC treated with five-fraction SBRT. These findings suggest that PTV D95% ≥40 Gy should be considered as a cut-off dose to prevent recurrence.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 5","pages":"2898-2907"},"PeriodicalIF":1.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complementary and Alternative Medicine (CAM) Use in Patients Undergoing Radiotherapy: Sex-specific Prevalence and Associations of Use Based on the S3 Guideline Complementary Medicine in Oncology Questionnaire.","authors":"Lukas Käsmann, Ralph Gurtner, Robert Rennollet, Judith Büntzel, Oliver Micke, Claus Belka, Montserrat Pazos, Ralph Mücke, Josefine Rauch, Jutta Hübner","doi":"10.21873/invivo.14097","DOIUrl":"https://doi.org/10.21873/invivo.14097","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed to assess the sex-specific prevalence and patterns of complementary and alternative medicine (CAM) use in patients undergoing radiotherapy, using the standardized questionnaire developed as part of the S3 Guideline on Complementary Medicine in Oncology.</p><p><strong>Patients and methods: </strong>Between August and December 2022, 112 out of 697 eligible cancer patients receiving radiotherapy were prospectively enrolled and completed a structured questionnaire assessing CAM use. The questionnaire included 38 CAM methods classified according to their potential for interactions.</p><p><strong>Results: </strong>Female participants generally used more CAM methods than male participants (median methods: 3 <i>vs.</i> 1, <i>p</i><0.001). The most frequently used CAM methods were vitamin D (46.4%), sports/exercise (33%) and vitamin A/C/E or beta-carotene (25%). At least one of the listed CAM methods was used by 79.5%. At least three of the listed CAM methods were used by 52 (46.4%) patients. Thirty-six (32.1%) and 54 (48.2%) patients used CAM methods with known or potential interactions, while 76 (67.9%) used methods with no known interactions. In addition, a higher number of female patients used uncertain methods or medications compared to males (<i>p</i>=0.022). The desire for counseling was very similar between both sexes, with no significant difference (<i>p</i>=0.973).</p><p><strong>Conclusion: </strong>The high rate of CAM utility before radiotherapy, especially among females, and the use of uncertain methods, highlights the need for standardized questionnaires to identify potential interactions. This would help enhance patient safety through structured screening and counseling.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 5","pages":"2969-2975"},"PeriodicalIF":1.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Recurrent Endometrial Cancer With Peritoneal Carcinomatosis.","authors":"Evangelos D Lolis, Dimitrios Kyziridis, Apostolos Kalakonas, Antonios-Apostolos Tentes","doi":"10.21873/invivo.14083","DOIUrl":"https://doi.org/10.21873/invivo.14083","url":null,"abstract":"<p><strong>Background/aim: </strong>Peritoneal carcinomatosis of recurrent endometrial cancer (EC) is a rare clinical entity with dismal prognosis. The purpose of this study was the presentation of the outcomes of patients with peritoneal carcinomatosis from recurrent endometrial cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).</p><p><strong>Patients and methods: </strong>The files of the patients with recurrent EC and peritoneal carcinomatosis treated with CRS and HIPEC between 2000 and 2024 were retrospectively reviewed. Clinical and histopathological variables were correlated to survival, morbidity, and mortality.</p><p><strong>Results: </strong>CRS plus HIPEC was performed in 23 female patients, mean age 60.4±7.9 (48-75) years. The mean peritoneal cancer index was 10.6±6 (3-39). Complete or near-complete cytoreduction was possible in 82.6% of patients. The incidence of severe morbidity and hospital mortality was 8.68% and 0%, respectively. Recurrence was recorded in 47% of patients. The overall 5- and 10-year survival was 78%. The completeness of cytoreduction score was identified as the single possible prognostic variable of survival.</p><p><strong>Conclusion: </strong>Complete cytoreduction combined with HIPEC appears to offer significant survival benefit with low morbidity in patients with recurrent EC and peritoneal carcinomatosis.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 5","pages":"2832-2841"},"PeriodicalIF":1.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial Experience With Proton Beam Therapy for Pancreatic Cancer at Shonan Kamakura General Hospital.","authors":"Shintaro Shiba, Sachika Shiraishi, Kazuya Koizumi, Yutaka Fujimoto, Naoto Ishiai, Koichi Tokuuye, Motoko Omura","doi":"10.21873/invivo.14101","DOIUrl":"https://doi.org/10.21873/invivo.14101","url":null,"abstract":"<p><strong>Background/aim: </strong>In Japan, proton beam therapy (PBT) for locally advanced pancreatic cancer was administered under an advanced medical treatment system until 2022; since then, it has been covered by national insurance. Our hospital initiated PBT for pancreatic cancer in July 2022. This study evaluated the clinical outcomes of PBT for pancreatic cancer after the initiation of national insurance coverage and assessed whether our initial experience at our hospital reproduced previously reported results.</p><p><strong>Patients and methods: </strong>This study included 10 patients with pancreatic cancer confirmed as inoperable due to locally advanced stage, comorbidity, or refusal to undergo surgery, without distant metastasis. All patients received a total PBT dose of 67.5 Gy (relative biological effectiveness) delivered in 25 fractions.</p><p><strong>Results: </strong>The median follow-up durations for all and surviving patients were 13.9 months (range=3.9-24.6 months) and 19.5 months (range=8.1-24.6 months), respectively. The 1- and 2-year overall survival and local control rates were 70% and 35%, and 89% and 89%, respectively. No grade 3 or higher acute or late non-hematological toxicities associated with PBT were observed.</p><p><strong>Conclusion: </strong>The clinical outcomes at the newly established PBT facility were comparable and reproducible to those observed in patients treated under the previous advanced medical treatment system.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 5","pages":"3001-3007"},"PeriodicalIF":1.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}